Ensysce Biosciences, Inc. Common Stock (ENSC)
Ensysce Biosciences, Inc. develops innovative drug delivery technologies aimed at improving safety and efficacy in pain management and other therapeutic areas. The company focuses on creating proprietary prodrug platforms that enhance pharmacological control and reduce abuse potential of opioids and other drugs.
Company News
Ensysce Biosciences advanced multiple clinical initiatives in Q2 2025, including launching a Phase 3 trial for PF614, completing enrollment in an overdose prevention study, and receiving a patent notice for its OUD program.
Ensysce Biosciences reported Q2 2025 results, advancing its PF614 opioid program to Phase 3 and achieving milestones in overdose-protection studies. The company reported a narrower GAAP loss of $(0.79) per share, with revenue primarily from federal grants.
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion. AMD shares dipped 3.8% to $165.49 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Con...
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,560% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.